UK trading ended on a pessimistic note this afternoon as Europe's second largest drugmaker, AstraZen...
UK trading ended on a pessimistic note this afternoon as Europe's second largest drugmaker, AstraZeneca, dropped on fear its cholesterol drug won't receive approval for sale in the US. Meanwhile, the benchmark FTSE 100 still lingers above the 4,000 mark after losing just 1.20 points today to 4,073.60. AstraZeneca shed 83p to 2,482p after a report made by US regulators revealed that the drugmaker's Crestor cholesterol drug may drug may pose more of a risk to the kidneys than do similar pills. BT Group dropped 5.5p to 191p after broker Cazenove & Co. lowered its recommen...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
